Regeneron Pharma

REGN executed a sharp V-shaped recovery today, extending a pre-market decline to $646.25 (down 0.76%) before plunging to $638.445 in regular trading, then rallying strongly to close at $651.91, essentially recouping yesterday's loss. The recent pressure stems from a failed Phase III clinical trial and ensuing securities class action lawsuits, which elevated market perception of pipeline risk. However, the intraday rebound signals renewed market confidence in the company's fundamental support following the initial shock. On the financial front, Q1 revenue of $3.605 billion surged 19% year-over-year, demonstrating top-line resilience; yet EPS and net profit declined 7.15% and 10.08% respectively, pointing to cost pressures. Valued at a P/E of 15.58 and down 20.61% from the 52-week high of $821.11, the stock sits near its 60-day moving average of $652.995. Analyst sentiment remains mixed: the latest call includes a $1,000 price-target hike, while Morgan Stanley cut to $730 and Piper Sandler turned pessimistic, reflecting the market's reassessment of trial-failure risks. Upcoming earnings should provide further clarity on business momentum.

Regeneron declined approximately 3.4% to $651.18 today, primarily pressured by the recent disclosure of a failed Phase III clinical trial that has triggered securities litigation, while the stock also underperformed competitors. Q1 2026 revenues reached $3.605 billion, up 19.04% year-over-year, but earnings per share fell 7.15% to $6.75 while net profit declined 10.08%, reflecting a disconnect between revenue growth and profitability. The stock has fallen 20.7% from its 52-week high of $821.11 and declined 16.12% year-to-date, currently trading slightly below the 20-day moving average of $653.50. Analyst sentiment remains divided: institutions including JPMorgan raised price targets to $1,000, while Morgan Stanley lowered its target to $730, reflecting divergent assessments of the company's future prospects.

Regeneron edged up 0.45% to $675.19 today as pre-market momentum from its selection in FDA's accelerated manufacturing review program—which had lifted it to $686.55—gave way to profit-taking; the stock remains down 13.03% year-to-date and 17.77% below its 52-week high of $821.11. Intraday peaks at $678.67 (10:25 ET) were not sustained, with the stock finishing at $675.19 and weakening further to $675.20 after hours. Headwinds include a failed Phase III trial triggering securities litigation and Morgan Stanley's reduction of its price target to $730; however, divergent analyst sentiment is evident as another firm has raised its target to $1,000. Q1 results show revenue growth of 19.04% year-over-year to $3.605 billion offset by a 10.08% decline in net profit to $727.2 million, compressing net margin from 21.74% to 20.17%—a profit-quality concern. Valuation multiples appear measured at 16.14x P/E and 2.27x P/B, while its inclusion in the FDA's pilot program signals research credibility; the key risk remains clinical execution and restoring margin accretion.

REGN declined roughly 0.67% today, primarily driven by profit-taking following prior strength, as shares rallied to $682.875 in pre-market trading but fell to $670.02 during the regular session, reflecting the market's active digestion of recent headwinds. Morgan Stanley recently lowered its price target to $730, while Piper Sandler issued a pessimistic outlook, and the company faces class-action litigation from shareholders. On the bright side, REGN was selected for FDA's accelerated manufacturing review pilot program, Dupilumab demonstrated improved outcomes in Phase 2 trials for eosinophilic granulomatosis with polyangiitis (EoG), and Cemdisiran received priority review status for generalized myasthenia gravis (gMG), providing support across multiple pipeline programs. At $672.15, the stock is down 13.42% year-to-date and trades 18.14% below its 52-week high of $821.11, though it remains above the 60-day moving average of $657.72, suggesting medium-term stability despite ongoing market disagreement regarding valuation upside.

REGN declined modestly in today's session, with regular trading closing at $676.69 versus the prior close of $678.94, down 0.33%, though intraday prices reached $691.13 (09:50 ET). Recent analyst activity has weighed on the stock: Piper Sandler turned pessimistic, Morgan Stanley lowered its price target to $730, and shareholder litigation concerns have also dampened sentiment. From a price perspective, the stock is down 12.83% year-to-date and has retraced 17.59% from its 52-week high of $821.11. After-hours activity extended the decline, with prices moving toward $672. On the positive side, Dupilumab showed improved outcomes in Phase 2 trials for eosinophilic granulomatosis with gastrointestinal involvement (EoG), and Regeneron was selected for FDA's fast-track manufacturing review program.